Close Menu

Natera

The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.

Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.

The firm recently described circumstances in which the fraction of host or donor DNA could be altered, and plans new approaches to data interpretation.

As a result of the expanded coverage, Natera said it believes there are currently 139 million people covered in the US for average risk NIPT.

Natera said that the expanded coverage by Centene will add 24 million people for whom the Panorama noninvasive prenatal test will be covered.

Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."

Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.

The randomized, Phase II trial will test ctDNA-guided second-line adjuvant therapy for stage II and III hormone receptor-positive, HER-2 negative breast cancer.

The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.

News items for in vitro diagnostics industry for the week of Sept. 14, 2020.

Pages